Interaction of CYP1B1, cigarette-smoke carcinogen metabolism, and lung cancer risk

International Journal of Molecular Epidemiology and Genetics

Volumn 1, Issue 4, 2010, Pages 295-309

  Church, Timothy R ^a   Haznadar, Majda ^b,f   Geisser, Mindy S ^a   Anderson, Kristin E ^a   Caporaso, Neil E ^c   Le, Chap ^a   Abdullah, Salwan B ^b   Hecht, Stephen S ^d   Oken, Martin M ^e   van Ness, Brian ^b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b Institute of Human Genetics   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d UNIVERSITY OF MINNESOTA   (United States)

^e UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^f Genetics and Cell Development   (United States)

Author keywords

Biomarkers; Genetics; Single nucleotide polymorphism; Smoking; SNP

Indexed keywords

4 (METHYLNITROSAMINO) 1 (3 PYRIDYL) 1 BUTANONE; CARCINOGEN; CIGARETTE SMOKE; CYTOCHROME P450 1B1; EPOXIDE HYDROLASE; GLUTATHIONE TRANSFERASE P1; POLYCYCLIC AROMATIC HYDROCARBON;

ADULT; AGED; ARTICLE; CANCER RISK; CARCINOGEN DNA INTERACTION; CASE CONTROL STUDY; CIGARETTE SMOKING; CLINICAL ASSESSMENT; CONTROLLED STUDY; DNA EXTRACTION; FEMALE; GENE INTERACTION; GENETIC ANALYSIS; GENOTYPE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LUNG CANCER; LYMPHOCYTE; MAJOR CLINICAL STUDY; MALE; METABOLISM; SINGLE NUCLEOTIDE POLYMORPHISM;

NICOTIANA TABACUM;

EID: 78449258014     PISSN: None     EISSN: 19481756     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. International Agency for Research on Cancer. Tobacco Smoke and Involuntary Smoking. Lyon, FR: IARC; 2004. p 33-1187.
2. International Agency for Research on Cancer. Smokeless Tobacco and Tobacco-Specific Nitrosamines. Lyon, FR: IARC; 2007. p 548-553.
3. Straif K, Baan R, Grosse Y, Secretan B, El Ghissassi F, Cogliano V. Carcinogenicity of polycyclic aromatic hydrocarbons. Lancet Oncol 2005;6 (12):931-932.
4. Hecht SS. Tobacco carcinogens, their biomarkers and tobacco-induced cancer. Nat Rev Cancer 2003;3(10):733-744.
5. Jalas JR, Hecht SS, Murphy SE. Cytochrome P450 enzymes as catalysts of metabolism of 4- (methylnitrosamino)-1-(3-pyridyl)-1-butanone, a tobacco specific carcinogen. Chem Res Toxicol 2005;18(2):95-110.
6. Hecht SS. Biochemistry, biology, and carcinogenicity of tobacco-specific N-nitrosamines. Chem Res Toxicol 1998;11(6):559-603.
7. Cooper CS, P. L. Grover, and P. Sims. The metabolism and activation of benzo[a]pyrene. Prog- Drug Metab 1983;7:295-396.
8. Church TR, Anderson KE, Caporaso NE, Geisser MS, Le CT, Zhang Y, Benoit AR, Carmella SG, Hecht SS. A prospectively measured serum biomarker for a tobacco-specific carcinogen and lung cancer in smokers. Cancer Epidemiol Biomarkers Prev 2009;18(1):260-266.
9. Hecht SS, Chen M, Yagi H, Jerina DM, Carmella SG. r-1,t-2,3,c-4-Tetrahydroxy-1,2,3,4-tetrahydrophenanthrene in human urine: a potential biomarker for assessing polycyclic aromatic hydrocarbon metabolic activation. Cancer Epidemiol Biomarkers Prev 2003;12(12):1501-1508.
10. Hecht SS, Carmella SG, Yoder A, Chen M, Li ZZ, Le C, Dayton R, Jensen J, Hatsukami DK. Comparison of polymorphisms in genes involved in polycyclic aromatic hydrocarbon metabolism with urinary phenanthrene metabolite ratios in smokers. Cancer Epidemiol Biomarkers Prev 2006;15(10):1805-1811.
11. Gohagan JK, Prorok PC, Hayes RB, Kramer BS. The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial of the National Cancer Institute: History, organization, and status. Control Clin Trials 2000;21(6 Suppl S):251S-272S.
12. Rothman KJ, Greenland S, editors. Modern Epidemiology. 2nd ed. Philadelphia, PA: Lippincott- Raven; 1998. xiii, 737 p.
13. Van Ness B, Ramos C, Haznadar M, Hoering A, Haessler J, Crowley J, Jacobus S, Oken M, Rajkumar V, Greipp P, Barlogie B, Durie B, Katz M, Atluri G, Fang G, Gupta R, Steinbach M, Kumar V, Mushlin R, Johnson D, Morgan G. Genomic variation in myeloma: design, content, and initial application of the Bank On A Cure SNP Panel to detect associations with progression-free survival. BMC Med 2008;6:26.
14. Carmella SG, Yoder A, Hecht SS. Combined analysis of r-1,t-2,3,c-4-tetrahydroxy-1,2,3,4- tetrahydrophenanthrene and 4- (methylnitrosamino)-1-(3-pyridyl)-1-butanol in smokers' plasma. Cancer Epidemiol Biomarkers Prev 2006;15(8):1490-1494.
15. Hecht SS. Tobacco smoke carcinogens and lung cancer. J Natl Cancer Inst 1999;91(14):1194-1210.
16. Hardenbol P, Baner J, Jain M et al. Multiplexed genotyping with sequence-tagged molecular inversion probes. Nat Biotechnol 2003;21 (6):673-678.
17. Greenland S, Pearl J, Robins JM. Causal diagrams for epidemiologic research. Epidemiology 1999;10(1):37-48.
18. Peto RLA, Boreham J et al. Mortality from smoking in developed countries 1950-2000: Indirect estimates from National Vital Statistics: Oxford University Press; 2006.
19. Biesalski HK, Bueno de Mesquita B, Chesson A et al. European Consensus Statement on Lung Cancer: risk factors and prevention. Lung Cancer Panel. CA Cancer J Clin 1998;48(3):167-176; discussion 164-166.
20. Hecht SS. Recent studies on mechanisms of bioactivation and detoxification of 4- (methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK), a tobacco-specific lung carcinogen. Crit Rev Toxicol 1996;26(2):163-181.
21. Lin P, Hu SW, Chang TH. Correlation between gene expression of aryl hydrocarbon receptor (AhR), hydrocarbon receptor nuclear translocator (Arnt), cytochromes P4501A1 (CYP1A1) and 1B1 (CYP1B1), and inducibility of CYP1A1 and CYP1B1 in human lymphocytes. Toxicol Sci 2003;71(1):20-26.
22. Hoffman EC, Reyes H, Chu FF et al. Cloning of a factor required for activity of the Ah (dioxin) receptor. Science 1991;252(5008):954-958.
23. Jiang BH, Rue E, Wang GL, Roe R, Semenza GL. Dimerization, DNA binding, and transactivation properties of hypoxia-inducible factor 1. J Biol Chem 1996;271(30):17771-17778.
24. Whitlock JP, Jr. Induction of cytochrome P4501A1. Annu Rev Pharmacol Toxicol 1999;39:103-125.
25. Alexander DL, Zhang L, Foroozesh M, Alworth WL, Jefcoate CR. Metabolism-based polycyclic aromatic acetylene inhibition of CYP1B1 in 10T1/2 cells potentiates aryl hydrocarbon receptor activity. Toxicol Appl Pharmacol 1999;161 (2):123-139.
26. Bandiera S, Weidlich S, Harth V, Broede P, Ko Y, Friedberg T. Proteasomal degradation of human CYP1B1: effect of the Asn453Ser polymorphism on the post-translational regulation of CYP1B1 expression. Mol Pharmacol 2005;67(2):435-443.
27. Mammen JS, Pittman GS, Li Y, Abou-Zahr F, Bejjani BA, Bell DA, Strickland PT, Sutter TR. Single amino acid mutations, but not common polymorphisms, decrease the activity of CYP1B1 against (-)benzo[a]pyrene-7R-trans-7,8-dihydrodiol. Carcinogenesis 2003;24(7):1247-1255.
28. Aklillu E, Ovrebo S, Botnen IV, Otter C, Ingelman-Sundberg M. Characterization of common CYP1B1 variants with different capacity for benzo[a]pyrene-7,8-dihydrodiol epoxide formation from benzo[a]pyrene. Cancer Res 2005;65 (12):5105-5111.
29. Nebert DW, Roe AL, Dieter MZ, Solis WA, Yang Y, Dalton TP. Role of the aromatic hydrocarbon receptor and [Ah] gene battery in the oxidative stress response, cell cycle control, and apoptosis. Biochem Pharmacol 2000;59(1):65-85.
30. Nebert DW, Benedict, W. F., and Kouri, R. E. Chemical Carcinogenesis. In: Ts'o POP, and DiPaolo, J. A, editor. New York: Marcel Dekker, Inc.; 1974. p 271-288.
31. Kellermann G, Shaw CR, Luyten-Kellerman M.Aryl hydrocarbon hydroxylase inducibility and bronchogenic carcinoma. N Engl J Med 1973;289(18):934-937.
32. Nebert DW, Dalton TP, Okey AB, Gonzalez FJ. Role of aryl hydrocarbon receptor-mediated induction of the CYP1 enzymes in environmental toxicity and cancer. J Biol Chem 2004;279 (23):23847-23850.
33. Chang JT, Chang H, Chen PH, Lin SL, Lin P. Requirement of aryl hydrocarbon receptor overexpression for CYP1B1 up-regulation and cell growth in human lung adenocarcinomas. Clin Cancer Res 2007;13(1):38-45.
34. Shimada T, Hayes CL, Yamazaki H et al. Activation of chemically diverse procarcinogens by human cytochrome P-450 1B1. Cancer Res 1996;56(13):2979-2984.
35. Meyer BK, Pray-Grant MG, Vanden Heuvel JP, Perdew GH. Hepatitis B virus X-associated protein 2 is a subunit of the unliganded aryl hydrocarbon receptor core complex and exhibits transcriptional enhancer activity. Mol Cell Biol 1998;18(2):978-988.
36. Kazlauskas A, Poellinger L, Pongratz I. Evidence that the co-chaperone p23 regulates ligand responsiveness of the dioxin (Aryl hydrocarbon) receptor. J Biol Chem 1999;274(19):13519-13524.
37. Hord NG, Perdew GH. Physicochemical and immunocytochemical analysis of the aryl hydrocarbon receptor nuclear translocator: characterization of two monoclonal antibodies to the aryl hydrocarbon receptor nuclear translocator. Mol Pharmacol 1994;46(4):618-626.
38. Pollenz RS, Sattler CA, Poland A. The aryl hydrocarbon receptor and aryl hydrocarbon receptor nuclear translocator protein show distinct subcellular localizations in Hepa 1c1c7 cells by immunofluorescence microscopy. Mol Pharmacol 1994;45(3):428-438.
39. Hankinson O. The aryl hydrocarbon receptor complex. Annu Rev Pharmacol Toxicol 1995;35:307-340.
40. Probst MR, Reisz-Porszasz S, Agbunag RV, Ong MS, Hankinson O. Role of the aryl hydrocarbon receptor nuclear translocator protein in aryl hydrocarbon (dioxin) receptor action. Mol Pharmacol 1993;44(3):511-518.
41. Denison MS, Elferink CF, Phelan D. The Ah receptor signal transduction pathway. In: Denison MS, W.G. H, editors. Toxicant-Receptor Interactions in the Modulation of Signal Transduction and Gene Expression. Philadelphia: Taylor & Francis; 1998. p 3-33.
42. Denison MS, Fisher JM, Whitlock JP, Jr. The DNA recognition site for the dioxin-Ah receptor complex. Nucleotide sequence and functional analysis. J Biol Chem 1988;263(33):17221-17224.